TrialPath

Find a study

Browse recruiting studies near you — free to check, always your choice.

Match me to a study

91 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

  • Kidney disease

    📍 Mayo Clinic in Arizona · Scottsdale, AZ · +4 more US sites · Get directions →

    The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-102 as a single agent and in combination with conventional anti-cancer drugs, pembrolizumab or trastuzumab deruxtecan(T-DXd) over a range of advanced and/or metastatic solid tumors.

    ✓ Study care freePhase 1Ages 18+Learn more →
  • Kidney disease

    Neurovascular Regulation During Exercise in Humans With Chronic Kidney Disease: Sympatholysis in CKD

    Studying how blood vessel and nerve control during exercise works in people with chronic kidney

    📍 Emory Clinic · Atlanta, GA · +1 more US site · Get directions →

    The goals of this project are to investigate the mechanisms and potential therapies related to exercise capacity in persons with chronic kidney disease (CKD).

    ✓ Study care freePhase 2Ages 40–75Learn more →
  • Dementia / Alzheimer'sParkinson's disease

    Phase 2 Trial of Tributyrin in People With Parkinson's Disease and Cognitive Impairments

    Testing whether a tributyrin supplement helps memory, thinking, and balance in adults with Parkinson

    📍 Domino's Farms · Ann Arbor, MI · Get directions →

    The goal of this clinical trial is to learn if taking a tributyrin supplement works to improve memory and thinking and walking and balance in adults with Parkinson disease Parkinson disease dementia. It will also learn about the safety of tributyrin supplementation.

    ✓ Study care freePhase 1Ages 45+Learn more →
  • Parkinson's disease

    Virtual tES Device Treatment for Parkinson's Disease Motor Symptoms

    Testing a non-invasive brain stimulation device to improve Parkinson’s movement problems

    📍 U LLC Headquarters · Cleveland, OH · Get directions →

    This study tests a new, non-invasive brain stimulation device called Sphere V3.0 to help improve movement problems in people with Parkinson's disease. The device delivers gentle electrical signals to the scalp using small electrodes placed on the head.

    ✓ Study care freePhase 1Ages 18–80Learn more →
  • Parkinson's disease

    Clinical Trial Evaluating the Efficacy and Safety of AGB101 for Treatment of Parkinson's Disease Related Psychosis

    Testing whether a low-dose seizure medicine can help Parkinson’s psychosis

    📍 Johns Hopkins · Baltimore, MD · Get directions →

    This clinical trial will test whether AGB101 (low-dose levetiracetam, 220 mg, extended release tablet) can improve symptoms of psychosis in Parkinson's disease. Participants will be asked to complete up to 5 in-person study visits over approximately 20 weeks.

    ✓ Study care freePhase 2Ages 40–85Learn more →
  • High blood pressureKidney disease

    📍 Research Site · Surprise, AZ · +17 more US sites · Get directions →

    International, Multicenter and Double-Blind study. The purpose is to measure the effect of baxdrostat in combination with dapagliflozin compared with baxdrostat/placebo on albuminuria, as well as safety, in participants with chronic kidney disease and high blood pressure.

    ✓ Study care freePhase 2Ages 18+Learn more →
  • Parkinson's disease

    A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease

    Testing a treatment in people with early Parkinson’s disease who have an LRRK2 gene test result

    📍 Banner Sun Health Research Institute · Sun City, AZ · +39 more US sites · Get directions →

    The goal of this Phase 2 clinical trial is to investigate the efficacy and safety of NEU-411 in men and women aged 40-80 years with early Parkinson's Disease (PD) who have predicted elevations in the activity of the "leucine-rich repeat kinase 2" ("LRRK2" for short) pathway based on their genetic profile. A DNA test will be used to identify the "LRRK2-driven" population with predicted elevation in the LRRK2 pathway.

    ✓ Study care freePhase 2Ages 40–80Learn more →
  • Kidney disease

    The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients

    Testing a 12-week diabetes medicine combination in kidney transplant patients with kidney disease

    📍 Toronto General Hospital · Toronto, Ontario · Get directions →

    The study aims to determine the short-term efficacy, mechanisms and safety of 12 weeks of dapagliflozin and semaglutide combination therapy in 20 KTR, with and without T2D.

    ✓ Study care freePhase 2Ages 18+Learn more →
  • Kidney disease

    Effect of Empagliflozin on Podocyte Specific Proteins in African American Veterans With NDKD

    Testing whether empagliflozin changes kidney filter injury proteins in African American Veterans

    📍 Washington DC Veterans Affairs Medical Center (688) · Washington D.C., DC · Get directions →

    Primary Objective:To study podocyte specific injury markers in African American Veterans with non-diabetic kidney disease(NDKD), on empagliflozin therapy. Primary Endpoint: Assess the effect of Empagliflozin on podocyte-specific proteins in exosomes isolated from subjects' urine, such as nephrin, podocalyxin and Wilms'Tumor (WT-1) protein.

    ✓ Study care freePhase 4Ages 19–90Learn more →
  • Parkinson's disease

    A Study of Buntanetap in Participants With PD

    Testing the long-term safety of buntanetap in people with Parkinson’s

    📍 University of Alabama at Birmingham · Birmingham, AL · +26 more US sites · Get directions →

    This study will examine the long-term safety of buntanetap in participants with PD. This will be a 36-month open-label safety study.

    ✓ Study care freePhase 2Ages 40–85Learn more →
  • Kidney disease

    Acute Equol Supplementation and Vascular Function in Women With and Without CKD

    Testing whether taking equol affects blood vessel function in women with or without CKD

    📍 University of Colorado Anschutz Medical Campus · Aurora, CO · Get directions →

    The risk of cardiovascular disease (CVD) is significantly elevated in patients with chronic kidney disease (CKD). Notably, women with CKD commonly experience menstrual disturbances induced by CKD, which may contribute to impaired vascular function and elevated CVD risk.

    ✓ Study care freePhase 2Ages 50–69WomenLearn more →
  • Kidney disease

    📍 SouthCoast Research Center, Inc. · Miami, FL · +1 more US site · Get directions →

    The goal of this clinical trial is to learn about the safety (good or bad) of giving two AION-301 intravenous (IV) infusions, in adults with Stage 3 Chronic Kidney Disease (CKD). It will also help to learn if AION-301 reduces the symptoms of CKD and/or progression.

    ✓ Study care freePhase 1Ages 35–75Learn more →
  • Type 2 diabetesHigh blood pressure

    Polypill for Prevention of Cardiomyopathy

    Testing a pill combination to prevent heart muscle disease in people with type 2 diabetes and high

    📍 UT Southwestern Medical Center · Dallas, TX · Get directions →

    This study will investigate the utility of a polypill-based strategy for patients with type 2 diabetes mellitus and high risk of heart failure (HF), as assessed via the WATCH-DM risk score. Polypill therapy will consist of empagliflozin 12.5 mg, losartan 25, 50 or 100 mg, and finerenone 10 mg daily.

    ✓ Study care freePhase 1Ages 18–100Learn more →
  • Parkinson's disease

    A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease

    Testing a carbidopa and levodopa extended-release capsule in people with Parkinson’s

    📍 Barrow Neurological Institute · Phoenix, AZ · +26 more US sites · Get directions →

    The primary purpose of this study is to evaluate efficacy and safety of CREXONT under real world conditions in participants with Parkinson disease (PD).

    ✓ Study care freePhase 4Ages 18+Learn more →
  • Kidney disease

    Intradialytic Exercise Combined With Creatine Monohydrate in Patients With Chronic Kidney Disease Undergoing Hemodialysis.

    Testing whether exercise during dialysis and creatine help people with chronic kidney disease

    📍 IMSS-Bienestar State Haemodialysis Centre · Colima, Coliima · Get directions →

    This study aims to evaluate the effects of creatine monohydrate supplementation and an intradialytic exercise program on body composition, biochemical parameters, and functional capacity in patients with chronic kidney disease (CKD) undergoing maintenance hemodialysis. The study will compare the independent and combined effects of these interventions over an 8-week period to determine their potential benefits in this patient population.

    ✓ Study care freePhase 1Ages 18+Learn more →
  • Kidney disease

    Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Adolescents With Early Stages of Chronic Kidney Disease

    Testing kidney disease drug effects and safety in teens with early CKD

    💵 May compensate

    📍 Instituto de atención Integral de Enfermedades Renales del Estado de Aguascalientes · Aguascalientes, Aguascalientes · Get directions →

    Chronic kidney disease (CKD) is highly prevalent in the state of Aguascalientes, Mexico, particularly among adolescents and young adults. Epidemiologic and histologic studies suggest that this burden is largely driven by reduced nephron endowment of prenatal origin, leading to compensatory glomerular hyperfiltration, adaptive podocytopathy, and persistent albuminuria at early stages of disease.

    ✓ Study care freePhase 4Ages 14–18Learn more →
  • Obesity / overweightHigh blood pressure

    Impact GLP-1 Agonists Following Bariatric

    Testing whether GLP-1 medicines after bariatric surgery affect weight and blood sugar

    📍 University of Missouri Hospital · Columbia, MO · Get directions →

    Glucagon-like peptide 1 (GLP-1) is a hormone that helps regulate blood glucose levels through improved insulin sensitivity and release of insulin from the pancreas, control hunger, induce satiety and plays a role in the metabolic health of a person. GLP-1 receptor agonists (GLP1-RAs) have been shown to be effective in achieving weight loss in patients with type 2 diabetes while improving blood glucose control.

    ✓ Study care freePhase 4Ages 18+Learn more →
  • Kidney disease

    Randomised Evaluation of Sodium Dialysate Levels on Vascular Events

    Testing whether two dialysate salt levels affect heart events and death

    📍 Royal Adelaide Hospital · Adelaide, · Get directions →

    This global study will assess the effect of randomising dialysis sites to one of two default dialysate sodium concentrations in current practice, 140mmol/l and 137mmol/l, on major cardiovascular events and death in patients receiving maintenance haemodialysis.

    ✓ Study care freePhase 4Ages 18+Learn more →
  • Type 2 diabetesKidney disease

    Mechanism of SGLT2 Inhibition in the Kidney

    Testing how SGLT2 medicines affect kidney function in type 2 diabetes

    💵 May compensate

    📍 University of Michigan · Ann Arbor, MI · Get directions →

    The goal of this open-label, non-randomized clinical trial is to determine what effects, if any, an FDA-approved drug class known as SGLT2 inhibitors (Canagliflozin or INVOKANA) has any protective effects on kidney function in Type 2 diabetes. We are looking for participants 18-80 years of age, who have had a clinical diagnosis of Type 2 diabetes for ≥ 3 years.

    ✓ Study care freePhase 4Ages 18–80Learn more →
  • Kidney disease

    A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease

    Testing safety and effects on urine protein in adults with APOL1 kidney disease

    📍 Research Site · Decatur, AL · +39 more US sites · Get directions →

    This is purpose of this study is to evaluate the safety, tolerability, and effect on Albuminuria of MZE829 in Adults with APOL1 Kidney Disease

    ✓ Study care freePhase 2Ages 18–68Learn more →
  • Kidney disease

    Anti-Inflammatory Treatment of Uremic Cardiomyopathy With Colchicine

    Testing colchicine for safety and effects in people with chronic kidney disease

    📍 Brigham and Women's Hospital · Boston, MA · Get directions →

    This study is designed to determine the efficacy and safety of colchicine in patients with chronic kidney disease.

    ✓ Study care freePhase 2Ages 21–80Learn more →
  • DepressionParkinson's disease

    Imaging Depression in Parkinson's Disease

    Studying brain changes linked to depression in people with Parkinson’s

    📍 Yale University · New Haven, CT · Get directions →

    The goal of this observational study is to identify targetable neural substrates of depression in Parkinson's Disease for the first time in people with Parkinson's between the ages of 40 and 80, who are experiencing symptoms of depression.

    ✓ Study care freePhase 2Ages 40–80Learn more →
  • High blood pressureCOPD (chronic lung disease)

    Breathe Easier With Tadalafil Therapy for Dyspnea in COPD-PH

    Testing tadalafil to see if it improves shortness of breath in COPD with high blood pressure in the

    📍 Rocky Mountain Regional VA Medical Center, Aurora, CO · Aurora, CO · +4 more US sites · Get directions →

    The investigators will study whether the drug tadalafil improves shortness of breath in 126 Veterans with Chronic Obstructive Pulmonary Disease (COPD) and high blood pressure in the lungs. The investigators will also assess whether tadalafil improves quality of life, home daily physical activity, exercise endurance, the frequency of acute flares of COPD, blood pressure in the lungs, and lung function.

    ✓ Study care freePhase 2Ages 35–89Learn more →
  • Parkinson's disease

    Ketamine for Veterans With Parkinson's Disease

    Testing ketamine for depression in veterans with Parkinson’s disease

    📍 San Francisco VA Medical Center, San Francisco, CA · San Francisco, CA · Get directions →

    Parkinson's disease (PD) is a devastating illness that has a growing impact on Veterans. One of the most disabling symptoms is depression, which is common in PD and linked to poor quality of life and higher risk of suicide.

    ✓ Study care freePhase 2Ages 40–80Learn more →
  • Parkinson's disease

    Early Longitudinal Imaging in the Parkinson's Progressive Marker Initiative (PPMI) Using (18F)AV-133 (PPMI AV-133 Prodromal Imaging)

    Tracking how brain scans change over time in people with early Parkinson’s

    📍 Institute for Neurodegenerative Disorders · New Haven, CT · +1 more US site · Get directions →

    The study is a longitudinal, multi-center study to assess progression of \[18F\] AV-133 imaging in Prodromal PD participants. Participants will be followed for up to 24 months.

    ✓ Study care freePhase 2Ages 18+Learn more →
  • Kidney disease

    Study to Evaluate the Safety and Efficacy of the 10 GE Xenokidney in Patients With ESRD

    Testing a GE xenokidney transplant in people with ESRD for safety and effectiveness

    📍 Northwestern Memorial Hospital · Chicago, IL · +1 more US site · Get directions →

    The purpose of this study is to evaluate the safety and efficacy of the 10 GE Xenokidney in patients with ESRD who are either not eligible for conventional allogeneic kidney transplantation (Group 1) or are on an Organ Procurement and Transplantation Network (OPTN) kidney transplant waitlist, but are more likely to die or go untransplanted within 5 years than receive a kidney transplant (Group 2). The study consists of xenotransplantation followed by a 24-week Post-transplant Follow up Period (Part A) to evaluate the efficacy and safety objectives followed by a Long-term Follow-up Period (Part B) to evaluate participant survival, 10 GE Xenokidney survival, and screening for zoonotic infections.

    ✓ Study care freePhase 1Ages 40–70Learn more →
  • Kidney disease

    Bone in CKD Alkali Response (BICARb Pilot Trial)

    Testing whether potassium citrate improves bone health in people with chronic kidney disease

    📍 Albert Einstein College of Medicine · The Bronx, NY · +1 more US site · Get directions →

    The goal of this clinical trial is to test whether potassium citrate improves skeletal health in adults and children with chronic kidney disease. The main questions it aims to answer are: * To evaluate effects of potassium citrate treatment on bone quality and strength.

    ✓ Study care freePhase 2Ages 5–100Learn more →
  • DepressionParkinson's disease

    Psilocybin Therapy for Depression in Parkinson's Disease

    Testing whether psilocybin therapy improves depression symptoms in people with Parkinson’s disease

    📍 University of California, San Francisco · San Francisco, CA · Get directions →

    The purpose of this study is to understand whether people with Parkinson's Disease and depression have improvement in their symptoms after psilocybin therapy.

    ✓ Study care freePhase 2Ages 40–80Learn more →
  • Parkinson's disease

    Cortical Electrophysiology of Response Inhibition in Parkinson's Disease

    Studying how deep brain stimulation in Parkinson’s affects brain control of stopping actions

    📍 Emory University Hospital · Atlanta, GA · +1 more US site · Get directions →

    Patients with Parkinson's Disease will be studied before, during, and after a deep brain stimulation implantation procedure to see if the stimulation location and the size of the electrical field produced by subthalamic nucleus (STN) DBS determine the degree to which DBS engages circuits that involve prefrontal cortex executive functions, and therefore have a direct impact on the patient's ability to inhibit actions.

    ✓ Study care freePhase 4Ages 45–75Learn more →
  • Kidney disease

    Testosterone Treatment in Men With Chronic Kidney Disease

    Testing an oral testosterone medicine to raise testosterone in men with chronic kidney disease

    📍 Saint Louis Univeristy · St Louis, MO · Get directions →

    This study in being conducted in men who have low testosterone and chronic kidney disease. The investigators will evaluate the effects of an oral testosterone preparation, JATENZO, on testosterone levels and hemoglobin (red blood cells).

    ✓ Study care freePhase 2Ages 18–85MenLearn more →
  • High blood pressureDementia / Alzheimer's

    Impact of Intensive Treatment of SBP on Brain Perfusion, Amyloid, and Tau (IPAT Study)

    Testing whether tightly lowering high blood pressure slows brain changes tied to Alzheimer’s

    📍 University of Texas Southwestern Medical Center · Dallas, TX · Get directions →

    The purpose of this study is to determine if intensive lowering of systolic blood pressure (SBP), using FDA approved medications (antihypertensive), reduces Alzheimer's Disease pathology (i.e., excessive brain amyloid and tau protein deposition) in older adults at high risk for memory decline or dementia.

    ✓ Study care freePhase 2Ages 60–85Learn more →
  • Parkinson's disease

    A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)

    Testing the safety and effect of a gene therapy put into the brain for moderate Parkinson’s disease

    📍 Mayo Clinic · Phoenix, AZ · +33 more US sites · Get directions →

    The objective of this randomized, surgically controlled, double-blinded, Phase 2 study is to evaluate the safety and efficacy of AAV2-GDNF delivered to the putamen in subjects with moderate Parkinson's Disease.

    ✓ Study care freePhase 2Ages 45–75Learn more →
  • Parkinson's disease

    Low-dose Carbon Monoxide (HBI-002) Trial to Evaluate Safety, Tolerability, PK, and Biomarkers in Parkinson's Disease

    Testing an oral low-dose carbon monoxide liquid in people with Parkinson’s

    📍 Quest Research Institute · Farmington Hills, MI · Get directions →

    A phase 2a multicenter, randomized, double-blind, placebo-controlled multiple dose study to evaluate the safety, tolerability, pharmacokinetics, of HBI-002, an oral low-dose carbon monoxide (CO) liquid drug product, administered daily over 14 days in subjects with Parkinson's disease (PD).

    ✓ Study care freePhase 2Ages 40–80Learn more →
  • Kidney disease

    Study to Evaluate the Safety and Efficacy of the GGTA1 KO Thymokidney in Patients With ESRD

    Testing a new kidney tissue transplant to treat end-stage kidney disease

    📍 New York University Langone Health · New York, NY · Get directions →

    The purpose of this study is to evaluate the safety and efficacy of the GGTA1 KO Thymokidney in patients with end-stage renal disease (ESRD) who are either not eligible for conventional allogeneic kidney transplantation (Group 1) or are on an Organ Procurement and Transplantation Network (OPTN) kidney transplant waitlist, but are more likely to die or go untransplanted within 5 years than receive a kidney transplant (Group 2). The study consists of xenotransplantation followed by a 24-week Post-transplant Follow-up Period (Part A) to evaluate the efficacy and safety objectives followed by a Long-term Follow-up Period (Part B) to evaluate participant survival, GGTA1 KO Thymokidney survival, and screening for zoonotic infections.

    ✓ Study care freePhase 1Ages 40–70Learn more →
  • Parkinson's disease

    Pyridostigmine for the Treatment of Constipation in Parkinson Disease

    Testing pyridostigmine as a treatment for constipation in Parkinson disease

    📍 University of Vermont Medical Center · Burlington, VT · Get directions →

    Constipation is a common and debilitating non-motor symptom of Parkinson disease (PD) that often precedes the onset of classic motor symptoms by decades. There is no standardized algorithm for managing constipation in this patient population, nor are there dedicated treatments.

    ✓ Study care freePhase 2Ages 18+Learn more →
  • Obesity / overweightHigh blood pressure

    Optimizing Portal Hypertension With TIPS and Interval Metabolic Surgery for Advanced Liver Disease

    Testing treatments to lower high pressure in liver veins in people with advanced liver disease and

    💵 May compensate

    📍 Cleveland Clinic Main Campus · Cleveland, OH · Get directions →

    Cirrhosis is a form of advanced liver disease that can lead to serious complications, especially when combined with severe obesity. Many patients with cirrhosis also develop a condition called clinically significant portal hypertension (CSPH), which is increased pressure in the veins of the liver.

    ✓ Study care freePhase 4Ages 18–70Learn more →
  • Parkinson's disease

    Rehabilitation of Airway Protection in Parkinson's Disease

    Testing therapy to improve airway protection problems in Parkinson’s

    📍 Purdue University · West Lafayette, IN · +1 more US site · Get directions →

    Airway protective disorders are a prevalent and progressive consequence of Parkinson's Disease (PD), and often result in aspiration pneumonia which is the leading cause of death in PD. Despite this, a large number of patients with PD do not access specialized services to address these critical deficits.

    ✓ Study care freePhase 2Ages 50–90Learn more →
  • Obesity / overweightHigh blood pressureCOPD (chronic lung disease)

    Feasibility of Semaglutide in Advanced Lung Disease

    Testing whether semaglutide can be given safely to people with advanced lung disease

    📍 University of Pennsylvania Perelman School of Medicine · Philadelphia, PA · Get directions →

    The goal of this clinical trial is to learn whether semaglutide, an FDA-approved treatment for diabetes and obesity, is feasible and tolerable in patients with advanced lung disease. The main question\[s\] it aims to answer are: 1.

    ✓ Study care freePhase 1Ages 18–80Learn more →
  • Kidney disease

    Breakthrough - T1DM and Chronic Kidney Disease

    Testing an experimental treatment of Tegoprubart plus islet cells for diabetes and chronic kidney

    📍 The University of Chicago · Chicago, IL · Get directions →

    Single arm- subject treated with Tegoprubart and everolimus. The purpose of this research is to gather information on the safety and effectiveness of investigational regimen containing 2 experimental components: * An investigational drug called Tegoprubart and * Human pancreatic islet cells Both Tegoprubart and human pancreatic islet cells are considered investigational because they are not approved for use in the United States by the Food and Drug Administration (FDA).

    ✓ Study care freePhase 1Ages 18–70Learn more →
  • Parkinson's disease

    📍 Cornell University Weill Medical College · New York, NY · Get directions →

    This is a phase 1/2 clinical study to evaluate the safety, tolerability, feasibility, and preliminary efficacy of NouvNeu001 in patients with advanced Parkinson's Disease.

    ✓ Study care freePhase 1Ages 30–75Learn more →
  • Dementia / Alzheimer'sParkinson's disease

    18F-mFBG Cardiac Uptake With Lewy Body Dementia

    Testing a heart imaging tracer to see how Lewy body dementia affects nerve signals

    📍 Houston Methodist Neurological Institute · Houston, TX · Get directions →

    This is a Phase 2 study evaluating the positron-emitting radiopharmaceutical 18F-mFBG as an imaging agent for quantification of the effect of neurodegenerative diseases on myocardial sympathetic innervation. Effectiveness of 18F-mFBG imaging of the heart will be judged in terms of the quantitative difference between results for subjects with Lewy body and non-Lewy body neurologic disease as compared to historical data for healthy control subjects.

    ✓ Study care freePhase 2Ages 18+Learn more →
  • Parkinson's disease

    Tenapanor in Synucleinopathy-Related Constipation

    Testing tenapanor for constipation related to Parkinson’s disease

    📍 Cedar Valley Digestive Health Center · Waterloo, IA · Get directions →

    Investigation of tenapanor as a potential treatment for synucleinopathy-associated constipation

    ✓ Study care freePhase 2Ages 50–89Learn more →
  • Parkinson's disease

    Evaluation of Tau-Pathology in Sporadic and LRRK2 Parkinson's Disease

    Testing how much brain tau buildup is in people with Parkinson’s using PET scans

    📍 Institute for Neurodegenerative Disorders / XingImaging, LLC · New Haven, CT · Get directions →

    The study aims to evaluate the burden of tau pathology in people with Sporadic and LRRK2 PD via in vivo imaging using the tau tracer, \[18F\]PI-2620, and a high resolution PET camera, NeuroEXPLORER.

    ✓ Study care freePhase 2Ages 45–85Learn more →
  • Parkinson's disease

    A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations

    Testing two doses of an add-on medicine to levodopa for Parkinson’s with motor fluctuations

    📍 University of Arkansas for Medical Sciences · Little Rock, AR · +24 more US sites · Get directions →

    This is a Phase 2 study in people with Parkinson's disease who experience motor fluctuations while taking levodopa. The study will evaluate how effective two different doses of the study drug AP-472 are when added to levodopa treatment, compared with a placebo.

    ✓ Study care freePhase 2Ages 30–80Learn more →
  • Parkinson's disease

    BOOST-PD A Naturalistic Study on IPX-203 for Parkinson's Disease

    Testing a new long-acting levodopa dose to improve “on” time in Parkinson’s

    📍 Cleveland Clinic · Cleveland, OH · Get directions →

    The purpose of this study is to evaluate the effect of IPX203 (Crexont®) - the newest extended-release levodopa formulation - on the duration and quality of good on time, using a wearable device to monitor symptoms. 'Good on time' refers to a period (minutes to hours) when a patient experiences optimal symptom control due to effective medication and has better overall functioning without troublesome dyskinesias.

    ✓ Study care freePhase 4Ages 40+Learn more →
  • Kidney diseaseCrohn's / ulcerative colitis (IBD)

    Patient Preference for Subcutaneous vs. Intravenous Immune Therapy

    Comparing patient preferences for skin injections vs IV for immune therapy in kidney disease or

    📍 UPMC Hillman Cancer Center · Pittsburgh, PA · Get directions →

    The study will evaluate patient and Health Care Professional- reported preference for Subcutaneous (SC) compared with IV nivolumab administration or similarly for SC compared with IV pembrolizumab.

    ✓ Study care freePhase 2Ages 18+Learn more →
  • Kidney disease

    REgulatory T Cell Therapy to Achieve Immunosuppression REduction

    Testing a cell therapy to lower the chance of kidney transplant rejection

    📍 Mayo Clinic in Arizona · Phoenix, AZ · +2 more US sites · Get directions →

    The goal of this multi-national, multi-center, open-label, randomized Phase 2 trial is to determine the safety and efficacy of administering expanded regulatory T cells (TRK-001) to prevent allograft rejection in living donor renal transplant recipients. Enrolled subjects will be randomized to one of 2 study arms: Arm 1 subjects will receive standard of care immunosuppression Arm 2 subjects will receive initial standard of care (SOC) immunosuppression and a single infusion of TRK-001.

    ✓ Study care freePhase 2Ages 18–65Learn more →
  • Kidney disease

    Glucagon-like-peptide-1 Receptor Agonists in Patients Receiving Maintenance Dialysis

    Testing whether a weekly diabetes medicine is safe for people on dialysis

    📍 Unity Health Toronto · Toronto, Ontario · Get directions →

    This study aims to determine if GLP1RA is safe and tolerable in maintenance dialysis population, adherence, and feasibility of a larger definitive cardiovascular outcome trial in this population. Participants will be randomized 1:1 to either weekly subcutaneous semaglutide versus usual care and followed for 26 weeks.

    ✓ Study care freePhase 4Ages 18+Learn more →
  • Obesity / overweightKidney disease

    Obesity Management for Kidney TRANSPLANTation: OK-TRANSPLANT 2

    Studying weight-loss support for people with obesity and kidney disease who want a kidney transplant

    📍 London Health Sciences Centre · London, Ontario · Get directions →

    OK-TRANSPLANT 2 is a vanguard study for a large randomized, pragmatic, open-label trial. We will randomize participants with obesity, high-risk CKD/dialysis who are hoping for lose weight for the purpose of kidney transplant.

    ✓ Study care freePhase 4Ages 18+Learn more →
  • High blood pressureKidney disease

    Equol and Vascular Function in Women With Chronic Kidney Disease

    Testing whether equol affects blood vessel function in women with chronic kidney disease

    📍 University of Colorado Anschutz Medical Campus · Aurora, CO · Get directions →

    The risk of cardiovascular disease (CVD) is significantly elevated in patients with chronic kidney disease (CKD). Notably, women with CKD commonly experience menstrual disturbances induced by CKD, which may contribute to impaired vascular function and elevated CVD risk.

    ✓ Study care freePhase 2Ages 50+WomenLearn more →
  • Kidney disease

    A Study to Evaluate Safety, Tolerability and Efficacy of AP306 at Fixed Doses in Dialysis Participants With Hyperphosphatemia

    Testing a medicine given at fixed doses for high phosphate in adults on hemodialysis

    📍 R1 Therapeutics Clinical Trial Site · Huntsville, AL · +22 more US sites · Get directions →

    This study is being conducted to characterize the safety, tolerability, and efficacy of AP306 at fixed doses in adults with hyperphosphatemia receiving maintenance hemodialysis.

    ✓ Study care freePhase 2Ages 18+Learn more →
  • Obesity / overweightKidney disease

    Glucagon-Like Peptide-1 Receptor Agonist in ADPKD

    Testing a 1-year weight-loss medicine to slow kidney cyst growth in adults with ADPKD

    📍 University of Colorado - Anschutz Medical Campus · Aurora, CO · Get directions →

    The proposed clinical trial aims to assess if a year of treatment with a glucagon-like peptide 1 receptor agonist, a medication approved for weight management that also improves the body's response to glucose and insulin, can slow kidney growth in adults with autosomal dominant polycystic kidney disease who are overweight or obese. The study will also evaluate changes in abdominal fat and kidney metabolism using cutting-edge images techniques.

    ✓ Study care freePhase 2Ages 18–65Learn more →
  • Parkinson's disease

    rTMS to Improve Cognition in Parkinson's

    Testing whether noninvasive brain stimulation can improve thinking in people with Parkinson’s

    📍 Jesse Brown VA Medical Center, Chicago, IL · Chicago, IL · +1 more US site · Get directions →

    The purpose of this study is to examine safety, feasibility, and the behavioral and brain effects of a non-invasive treatment, repetitive transcranial magnetic stimulation (rTMS), for Veterans with Parkinson's disease or atypical parkinsonism and mild impairments in their thinking. The hypothesis is that rTMS can improve thinking for people with Parkinson's disease or atypical parkinsonism who are experiencing mild problems with their thinking ability.

    ✓ Study care freePhase 1Ages 50+Learn more →
  • Parkinson's disease

    Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis

    Comparing treatments to see which works better for hallucinations in Parkinson’s disease

    📍 Southern Arizona VA Health Care System, Tucson, AZ · Tucson, AZ · +23 more US sites · Get directions →

    Patients with Parkinson's disease (PD) sometimes experience symptoms affecting their movement, such as slowness, tremor, stiffness, and balance or walking problems. Many patients also have other symptoms not related to movement, called non-motor symptoms, which may affect one's mood or emotions, memory or thinking, or cause one to see or hear things that aren't real (hallucinations) or believe things that aren't true (delusions).

    ✓ Study care freePhase 4Ages 40+Learn more →
  • Parkinson's disease

    Wearable Biofeedback for Swallowing Disorders Rehabilitation in Stroke and Parkinson Disease

    Testing a wearable sensor that gives feedback for swallowing therapy in Parkinson’s

    📍 Purdue University · West Lafayette, IN · Get directions →

    Dysphagia, or difficulty swallowing, is a common symptom of many neurological diseases but its treatment is not well established or easily accessible. To start addressing this gap, the researchers developed and validated a cost-effective wearable surface electromyography (sEMG) biofeedback sensor technology (i-Phagia), optimized to record muscle activity from the head/neck and provide biofeedback to patients and adherence data to clinicians during swallow therapy.

    ✓ Study care freePhase 2Ages 50–90Learn more →
  • Parkinson's disease

    Reducing Falls With Varenicline in Hypocholinergic Parkinson Disease

    Testing varenicline to reduce falls and improve walking multitasking in Parkinson’s

    📍 University of Michigan · Ann Arbor, MI · Get directions →

    This trial aims to test whether one year of Varenicline, when compared to placebo, can reduce fall risk and show improvement in the ability to multitask while walking. Participants that are eligible after screening for the study will be randomized to receive Varenicline or placebo.

    ✓ Study care freePhase 2Ages 45+Learn more →
  • Kidney disease

    Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma

    Testing orellanine in kidney cancer patients on chronic hemodialysis to see if it is safe and may

    📍 Stanford · Palo Alto, CA · +2 more US sites · Get directions →

    A phase I/II, open-label, study to determine the safety and preliminary efficacy of orellanine in patients with metastatic clear-cell or papillary renal carcinoma who have failed standard-of-care therapy. All participants must have end-stage kidney disease and be receiving stable chronic hemodialysis.

    ✓ Study care freePhase 1Ages 18+Learn more →
  • Dementia / Alzheimer'sParkinson's diseaseMultiple sclerosis (MS)

    Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers

    Testing safety of a PET imaging tracer in people with ALS, AD, MS, PD

    📍 UCSF · San Francisco, CA · +2 more US sites · Get directions →

    This is a Phase 1/2 study to evaluate the safety and tolerability of 18F-OP-801 in subjects with ALS, AD, MS, PD and age-matched HVs. 18F-OP-801 is intended as a biomarker for PET imaging of activated microglia and macrophages in regions of neuroinflammation.

    ✓ Study care freePhase 1Ages 18–80Learn more →
  • Kidney disease

    A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease

    Comparing doses of a new medicine to see effects on kidney damage in chronic kidney disease

    📍 N America Res Inst - San Dimas · San Dimas, CA · +17 more US sites · Get directions →

    The study evaluates the safety of different doses of a new medicine called NNC0519 0130. It also looks into how the medicine may improve kidney function in participants with chronic kidney disease with or without type 2 diabetes, living with overweight or obesity.

    ✓ Study care freePhase 2Ages 18+Learn more →
  • Kidney disease

    Study to Assess the Effects of Angiopoietin-like Protein 3 (ANGPTL3) Inhibition in Adult Participants With Diabetic Kidney Disease

    Testing medicines that lower ANGPTL3 in adults with diabetic kidney disease

    📍 Apogee Clinical Research, LLC · Huntsville, AL · +39 more US sites · Get directions →

    This study is researching experimental drugs called ALN-ANG3 and evinacumab (called "study drugs"). The study is focused on participants who have diabetic kidney disease.

    ✓ Study care freePhase 2Ages 18–80Learn more →
  • Showing the first 60 of 91. Add filters or a location to narrow down.